Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 11/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14061899 | 0.86 | HTR2A (0.59) | HTR7HTR2AHTR2CCDK4CCND1 | |
| SCHEMBL4944128 | 0.85 | HTR7 (0.52) | HTR7HTR6HTR2AHTR2CPRMT5 | |
| SCHEMBL7256513 | 0.82 | HTR7 (0.51) | HTR7HTR6HTR2AHTR2CHTR1D | |
| SCHEMBL31121493 | 0.82 | HTR7 (0.54) | HTR7HTR6HTR2AHTR2CPRMT5 | |
| SCHEMBL5621531 | 0.82 | HTR7 (0.54) | HTR7HTR6HTR2AHTR2CPRMT5 | |
| Dimethylamine SCHEMBL18941222 | 0.81 | HTR2A (0.55) | HTR7HTR2AHTR2C | |
| SCHEMBL18239404 | 0.81 | HTR7 (0.53) | HTR7HTR6HTR2AHTR2CPRMT5 | |
| SCHEMBL31258100 | 0.81 | HTR2A (0.64) | HTR7HTR6HTR2AHTR2CHTR1D | |
| SCHEMBL7252922 | 0.81 | HTR2A (0.64) | HTR7HTR6HTR2AHTR2CHTR1D | |
| SCHEMBL26675197 | 0.81 | HTR7 (0.60) | HTR7HTR6HTR2AHTR2CPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | BRCA1, NQO2, NQO1 | HTR7 3745/4885HTR6 2563/4885HTR2A 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.